ACM
TARS icon

Altium Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Altium Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-70,573
Closed -$2.04M – 154
2021
Q2 		$2.04M Buy
+70,573
New +$2.2M 0.47% 82

Other funds holding TARS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Altium Capital Management's TARS Position: Q3 2021 in Review

Altium Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2021, closing a stake of 70,573 shares — an estimated $2.04M sold.

Altium Capital Management first reported a position in TARS in Q2 2021 and held it in 1 quarter. The position peaked at $2.04M in Q2 2021. 44 funds tracked by Wall St. Rank hold TARS as of Q3 2021.

  • Altium Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 70,573 Tarsus Pharmaceuticals shares in Q3 2021, an estimated $2.04M.
  • Altium Capital Management first reported a position in Tarsus Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's Tarsus Pharmaceuticals position peaked at $2.04M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.